SCHEMBL5147745

SCHEMBL5147745

CCOC(=O)[C@@H](N)Cc1ccc(Nc2nccc3ccncc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
XDH P47989 2/20 0.40
WNT3A P56704 1/20 0.39
MAPT P10636 5/20 0.38
KDM4E B2RXH2 4/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 1/20 0.37
CIT O14578 1/20 0.36
RAB9A P51151 2/20 0.36
EGFR P00533 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149495 0.93 EGFR (0.40) HDAC3HDAC1HDAC6XDHMAPT
SCHEMBL5260057 0.92 HDAC3 (0.40) HDAC3HDAC1HDAC6WNT3AALDH1A1
SCHEMBL5260061 0.92 HDAC3 (0.40) HDAC3HDAC1HDAC6WNT3AALDH1A1
SCHEMBL2980724 0.88 MEN1 (0.42) MAPTKDM4ENPSR1CYP1A2CYP3A4
SCHEMBL5262210 0.88 MEN1 (0.42) MAPTKDM4ENPSR1CYP1A2CYP3A4
SCHEMBL6537407 0.86 SLC7A5 (0.43) HDAC3HDAC1HDAC6WNT3AKDM4E
SCHEMBL2990667 0.86 SLC7A5 (0.43) HDAC3HDAC1HDAC6WNT3AKDM4E
SCHEMBL5262134 0.84 CIT (0.39) HDAC3HDAC1HDAC6ALDH1A1CIT
SCHEMBL5262133 0.84 CIT (0.39) HDAC3HDAC1HDAC6ALDH1A1CIT
SCHEMBL2990961 0.81 TACR1 (0.40) MAPTCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 HDAC3 283/4885HDAC1 636/4885HDAC6 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.